Pharma stocks a defensive play, says Bhat – Moneycontrol.com

Published on Fri, May 04, 2012 at 18:34 |  Source : CNBC-TV18Updated at Fri, May 04, 2012 at 18:47   54893 Investors following Ranbaxy Labs. Share this News with them.0

One can buy defensive stocks like pharma says Dilip Bhat, Joint MD, Prabhudas Lilladher.

Bhat told CNBC-TV18, “We would be more comfortable towards pharmaceutical. It is a great space to be in even now particularly Ranbaxy and Dr. Reddy’s and in the midcap it could be Indoco Remedies.”

He further added, “ Ranbaxy Labs is one story which we are just in the process of doing a detailed coverage but that’s one stock which we feel has a potential to double over next 15-18 months. I think with the FDI approval coming, the stage is set for the core profits to really grow in a very big way for the company and of course the first to file will keep on increasing the cash flows for the company. So that pharmaceutical space looks pretty good, interesting, defensive at the same time chances of getting a reasonable return also appears to be pretty good.”

document.write(page_mob_footer);function poll_value(option){var option_selected = option;//alert(option_selected);document.getElementById(‘prce_opt’).value = option_selected;//alert(document.getElementById(‘mc_option’).value);document.mc_m3poll.action=”http://mmb.moneycontrol.com/india/messageboard/view_topic_msgs.php”;document.mc_m3poll.submit();}function msg_close(){$(‘#pollM3Almc’).hide(‘slow’);}document.getElementById(“m3Ppoll_top”).innerHTML=””;document.getElementById(“m3Ppoll_top”).innerHTML=document.getElementById(“article_stk_poll”).innerHTML; function postquote(keysearch) { len = keysearch.companyname.value.length; if(len 10) { tempvar=companyname; flag1=”true”; break; } else { j=i+1; result= companyname.charAt(i); preval=companyname.charAt(j); if(result==” ” || preval==” ” || result==”.” || preval==”.” || len=0; i–) revstr+=str.charAt(i) return revstr; } function sector_newsletter(){ var email = document.getElementById(“email_newsletter”).value; emailRe = /^\w+([\.-]?\w+)*@\w+([\.-]?\w+)*\.(\w{2}|(com|net|org|edu|int|mil|gov|arpa|biz|aero|name|coop|info|pro|museum))$/ if(email==” || email==’Enter email address’) { alert(“Enter Email address.”); document.getElementById(’email_newsletter’).focus(); return false; }else if(!emailRe.test(email)) { alert(“Enter Valid Email”); document.getElementById(’email_newsletter’).focus(); return false; }else{ var emailstr = toHex(email); var str = strrev(emailstr); document.nlfrm.action =’/sector-newsletters/index.php?email=’+str; return true; } } function tabs_news_rhs(a) { if(a==1) { document.getElementById(“news_mp”).style.display=”block”; document.getElementById(“news_ep”).style.display=”none”; document.getElementById(“rhs_tab_1”).className = “act”; document.getElementById(“rhs_tab_2”).className = “”; } else { document.getElementById(“news_mp”).style.display=”none”; document.getElementById(“news_ep”).style.display=”block”; document.getElementById(“rhs_tab_1”).className = “”; document.getElementById(“rhs_tab_2”).className = “act”; } }

IOB Q4 NII At `1,340 Cr Vs `1,215 Cr (YoY)

The latest earning numbers FIRST on CNBC-TV18Subscribe toMoneycontrol Newsletters

View the original article here

Buy Alembic Pharma; target of Rs 86: Nirmal Bang – Moneycontrol.com

Published on Sat, May 05, 2012 at 10:48 |  Source : Moneycontrol.comUpdated at Sat, May 05, 2012 at 11:14  0

Nirmal Bang is bullish on Alembic Pharma and has recommended buy rating on the stock with a target of Rs 86 in its May 2, 2012 research report.

“Alembic Pharma, sequential results are not comparable due to seasonality factor. Q4 is seasonally weak quarter for the company. Exports drove the sales growth for the quarter as well as for FY12. During the quarter exports grew by 28.1% yoy as compared to domestic growth of 7.5% yoy. For FY12 exports reported impressive growth of 41.2% as compared to 11.3% domestic growth. During the quarter R&D expenses have increased substantially to Rs 22.1 cr (6.5% of sales; includes one-time filing cost of NDA of Rs 5 cr) as against Rs 9.1 cr (2.4%) in Q3FY12 and Rs 15.7 cr (5.3%) in Q4FY11, on account of higher filings for European and Brazil regions and more Para IV and 505 (b) (2) filings. We have also incorporated higher R&D cost for future years (4.8% of sales in FY13E and FY14E as compared to 4.0% in FY12).”

“The company has filed four ANDAs and three DMFs during the quarter taking the cumulative filings to 45 ANDAs and 62 DMFs. It has received two approvals as well in Q4FY12 taking the total approvals to 19. Management expects domestic formulations growth to be strong however it would be limited by current capacity constraints. The management expect 15% growth in FY13 however it also feels that FY14 would be the turnaround year in terms of growth as new capacity would ease the current constraints and it would be able to take the full benefit of increasing demand.”

“For FY12-14, we expect Alembic Pharma’s revenues to grow at 15.6%. However, PAT is expected to grow faster i.e. 25.0% during the same period on account of favorable change in product mix, shift from API to formulations, launch of new products and higher economies of scale. We had initially recommended Alembic Pharma on 22nd March 2012 at Rs 43. Since then the stock has given 26% returns. We maintain our “BUY” with a revised target price of Rs. 86 (earlier Rs 97) indicating a potential upside of 59% over next two years. Major reason for revision in numbers is slow down in FY13 numbers due to constraints in capacity and higher R&D expenses,” says Nirmal Bang research report.  

Non-Institutions holding more than 90% in Indian cos   

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click on the attachment

document.write(page_mob_footer);function poll_value(option){var option_selected = option;//alert(option_selected);document.getElementById(‘prce_opt’).value = option_selected;//alert(document.getElementById(‘mc_option’).value);document.mc_m3poll.action=”http://mmb.moneycontrol.com/india/messageboard/view_topic_msgs.php”;document.mc_m3poll.submit();}function msg_close(){$(‘#pollM3Almc’).hide(‘slow’);}document.getElementById(“m3Ppoll_top”).innerHTML=””;document.getElementById(“m3Ppoll_top”).innerHTML=document.getElementById(“article_stk_poll”).innerHTML; function postquote(keysearch) { len = keysearch.companyname.value.length; if(len 10) { tempvar=companyname; flag1=”true”; break; } else { j=i+1; result= companyname.charAt(i); preval=companyname.charAt(j); if(result==” ” || preval==” ” || result==”.” || preval==”.” || len=0; i–) revstr+=str.charAt(i) return revstr; } function sector_newsletter(){ var email = document.getElementById(“email_newsletter”).value; emailRe = /^\w+([\.-]?\w+)*@\w+([\.-]?\w+)*\.(\w{2}|(com|net|org|edu|int|mil|gov|arpa|biz|aero|name|coop|info|pro|museum))$/ if(email==” || email==’Enter email address’) { alert(“Enter Email address.”); document.getElementById(’email_newsletter’).focus(); return false; }else if(!emailRe.test(email)) { alert(“Enter Valid Email”); document.getElementById(’email_newsletter’).focus(); return false; }else{ var emailstr = toHex(email); var str = strrev(emailstr); document.nlfrm.action =’/sector-newsletters/index.php?email=’+str; return true; } } function tabs_news_rhs(a) { if(a==1) { document.getElementById(“news_mp”).style.display=”block”; document.getElementById(“news_ep”).style.display=”none”; document.getElementById(“rhs_tab_1”).className = “act”; document.getElementById(“rhs_tab_2”).className = “”; } else { document.getElementById(“news_mp”).style.display=”none”; document.getElementById(“news_ep”).style.display=”block”; document.getElementById(“rhs_tab_1”).className = “”; document.getElementById(“rhs_tab_2”).className = “act”; } }

IOB Q4 NII At `1,340 Cr Vs `1,215 Cr (YoY)

The latest earning numbers FIRST on CNBC-TV18Subscribe toMoneycontrol Newsletters

View the original article here

Textile, pharma to get astro support: Astrostocktips – Moneycontrol.com

Published on Fri, May 04, 2012 at 09:38 |  Source : Moneycontrol.comUpdated at Fri, May 04, 2012 at 09:41  Like this story, share it with millions of investors on M30

By Satish Gupta of Astrostocktips

Today’s planetary position: Moon will be transiting in Virgo, Mars in Leo, Exalted Saturn in Libra. Sun & Jupiter in Aries.  Ketu & Venus in Taurus. Rahu in Scorpio.  Mercury in Pisces, Pluto in Sagittarius, Uranus in Pisces. Neptune in   Aquarius.

RAHU KAL TIME: – 10.30-12.00

Predicted with blessings of Lord Ganesha on 21st March 2012 “With the change in planetary position, LIQUOR sector will be receiving very strong astrological support. Accumulate United Spirit on dips” United Spirit was quoted around Rs 538 at that time. In a period of one month it appreciated by 45%. This sector will continue receiving astrological support.(21.04.12)

Looking to the planetary configuration following sectors will be getting astrological support:

Textile: Raymond, Arvind, Century & Bombay Dyeing etc

Pharma: Dr Reddy, Lupin & Cipla ect

Buy Titan on dips.

Note: Prediction about Infrastructure sector was made by us 3 months back on Zee Business on last Deepavali day.

New Samvat 2069 (Hindu New Year) will start from 23rd March 2012. Whenever New Samvat starts, based on planetary position / conjunction & aspect among planets, some new sectors commence out performing & many sectors, which were in momentum during last Samvat start underperforming.

It has been observed many times that investors / traders (not knowing this fact) keep investing /trading in such sectors,( whose astrological support is over) ?” resulting in  losses. It is suggested to consult your Financial Astrologer to know about the sectors.

Bullish trend started in Silver from 1stSeptember 2010, when Saturn entered Hast Nakshatra. On 28th August 2010, silver was quoted Rs 28700 /kg. In a period of less than 1 year it appreciated by 3 times approximately. Now on 20th September 2011, Saturn has left Hast Nakshatra & due to this change in planetary position, long term bullish trend in Silver is over for time being. Now, only when Saturn will have some combination with moon along with other planets, it can move up for shorter period.

One should trade only in the stocks of that sectors which are getting very strong astrologically support, since the chances of losing money in such stocks are very less.

Sectors which get strong ASTRO support are not normally affected by downfall in the market.

Although we predict sectors, it is not necessary that all stocks with in same sector should move up same day.

document.write(page_mob_footer); function postquote(keysearch) { len = keysearch.companyname.value.length; if(len 10) { tempvar=companyname; flag1=”true”; break; } else { j=i+1; result= companyname.charAt(i); preval=companyname.charAt(j); if(result==” ” || preval==” ” || result==”.” || preval==”.” || len=0; i–) revstr+=str.charAt(i) return revstr; } function sector_newsletter(){ var email = document.getElementById(“email_newsletter”).value; emailRe = /^\w+([\.-]?\w+)*@\w+([\.-]?\w+)*\.(\w{2}|(com|net|org|edu|int|mil|gov|arpa|biz|aero|name|coop|info|pro|museum))$/ if(email==” || email==’Enter email address’) { alert(“Enter Email address.”); document.getElementById(’email_newsletter’).focus(); return false; }else if(!emailRe.test(email)) { alert(“Enter Valid Email”); document.getElementById(’email_newsletter’).focus(); return false; }else{ var emailstr = toHex(email); var str = strrev(emailstr); document.nlfrm.action =’/sector-newsletters/index.php?email=’+str; return true; } } function tabs_news_rhs(a) { if(a==1) { document.getElementById(“news_mp”).style.display=”block”; document.getElementById(“news_ep”).style.display=”none”; document.getElementById(“rhs_tab_1”).className = “act”; document.getElementById(“rhs_tab_2”).className = “”; } else { document.getElementById(“news_mp”).style.display=”none”; document.getElementById(“news_ep”).style.display=”block”; document.getElementById(“rhs_tab_1”).className = “”; document.getElementById(“rhs_tab_2”).className = “act”; } }

IOB Q4 NII At `1,340 Cr Vs `1,215 Cr (YoY)

The latest earning numbers FIRST on CNBC-TV18Subscribe toMoneycontrol Newsletters

View the original article here